

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,359	06/23/2005	Eva Altmann	PA/4-32832A	3331
75074 7590 04/03/2908 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.			EXAMINER	
400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139		TRUONG, TAMTHOM NGO		
			ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			04/03/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

### Application No. Applicant(s) 10/540,359 ALTMANN ET AL. Office Action Summary Examiner Art Unit TAMTHOM N. TRUONG 1624 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 23 June 2005 (Prelim, amdt). 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

<ol> <li>Claim(s) <u>1-10</u> is/are pending in the application.</li> </ol>				
4a) Of the above claim(s) is/are withdrawn from consideration.				
5) Claim(s) is/are allowed.				
6) Claim(s) is/are rejected.				
7) Claim(s) is/are objected to.				
8) Claim(s) 1-10 are subject to restriction and/or election requirement.				
Application Papers				

# 9)☐ The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) \_\_\_\_ accepted or b) \_\_\_\_ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

a) All b) Some \* c) None of:

/	-/
1.🛛	Certified copies of the priority documents have been received.
2.	Certified copies of the priority documents have been received in Application No
3 🗆	Copies of the certified copies of the priority documents have been received in this National Si

application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patient Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTC/95/08) Paper No(s)/Mail Date	4) Interview Summary (PTO-413) Paper No(s)/Mail Date. 5. Action of Informat Pater Lapplication. 6) Other:	

Application/Control Number: 10/540,359 Page 2

Art Unit: 1624

#### Election/Restriction

The preliminary amendment of 6-23-05 is acknowledged.

Claims 1-10 are pending.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1, 2, and 5-9, drawn to compounds of formula (I) or (I');
   and pharmaceutical composition and process thereof; classified in class 514, subclass 266.3, and class 544, subclass 283.
- II. Claims 3, 4 and 10, drawn to compounds of formula (II) or (II'); pharmaceutical composition and process thereof; classified in class 514, subclass 539, and class 560, subclass 35.

Inventions Group I and II are related as mutually exclusive species in an intermediatefinal product relationship. Distinctness is proven for claims in this relationship if the
intermediate product is useful to make other than the final product, and the species are patentably
distinct (MPEP § 806.05(j)). In the instant case, the intermediate product is deemed to be useful
as another product such as a heat-sensitive recording material as evident by Otsuji et. al. (US
5,270,281) and the inventions are deemed patentably distinct because there is nothing of record
to show them to be obvious variants.

They also differ from each other because each group is drawn to a ring system that is distinct and patentable over each other. Essentially, these are **independent** inventions as compounds of one group can be utilized alone, and not in combination of those in other groups.

Note, the core of Group I is a bicyclic system while that of Group II is a simple monocyclic system. Clearly, a prior art that renders obvious one invention would not do so to the other.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above <u>and</u> there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include

(i) an election of a invention to be examined even though the requirement may be traversed (37

CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M. T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Tamthom N. Truong/

Tamthom N. Truong Examiner Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner, Art Unit 1624

3-27-08